Amgen is on pace to return to its pre-Horizon capital structure by the end of 2025. Learn why I upgrade AMGN stock from hold ...

- Encouraging progress supports near-term focus on lead wholly-owned program, CX-2051 (EpCAM PROBODY® ADC). Initial Phase 1a ...

What's on the horizon for the life sciences industry? Robin Johnson, PharmD, Gene Therapy Submissions Lead, inSeption Group What unique challenges do gene therapy submissions face compared to ...

This month is our safety and pharmacovigilance focus, so pharmaphorum's Hannah Blake interviewed Amgen's Vice President of Global Regulatory Affairs and Safety, Alan Morrison, to find out Amgen's ...

The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients ...

Based on Amgen’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $8.5 billion and a net profit of $2.83 billion. In comparison ...

Louis Navellier is a prominent American investor, author, and financial analyst, best known for his quantitative approach to ...

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $310.00. The ...

A dozen wake Technical Community College students signed letters of intent on Monday to work with Amgen. Amgen is planning a $1 billion expansion in Holly Springs. “This is a really good ...

His career has included stops at Eli Lilly, Novian Health and, for the last 16 years, Amgen. His tenure at Amgen included roles in sales and marketing for many of its hematology and oncology ...